HomeLilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site

Lilly breaks ground in Pennsylvania’s Lehigh Valley on a $3.5 billion site

Eli Lilly and Company has commenced building a $3.5 billion manufacturing facility in Pennsylvania’s Lehigh Valley.

The site is one of 10 new US manufacturing sites announced since 2020 and one of four among them dedicated to injectable medicines and devices.

Part of the company’s $50 billion push to expand medicine production in the US, the Lehigh Valley site will add capacity for the next generation of obesity treatments, including retatrutide, a first-in-class investigational GIP, GLP-1 and glucagon triple hormone receptor agonist.

By pairing a highly skilled workforce with advanced technologies and specialised manufacturing, the Lehigh Valley site will help support a reliable supply of safe, high-quality medicines. It will use state-of-the-art technologies, including machine learning, AI, digitally integrated systems and advanced data analytics, to drive right-first-time execution, with digital automation embedded throughout the site to streamline operations.

The facility will be built and operated to the highest standards for safety, quality and environmental stewardship, and Lilly is committed to being a good neighbour in Lehigh Valley and across Pennsylvania. The site is targeting a Leadership in Energy and Environmental Design (LEED) Gold certification, demonstrating Lilly’s focus on sustainable performance as it expands advanced manufacturing in the US.

Located in Fogelsville, Pennsylvania, USA, the site is expected to be operational by 2031.

- Advertisment -
- Advertisment -

Most Popular

Popular categories